NEW whitepaper: Tackling therapeutic inertia to boost patient outcomes
Read this exclusive whitepaper to gain key insights from patient experts and pharma leaders from Ipsen, Novartis, and WeFight on pharma can prevent lags in care, suboptimal patient outcomes and growing healthcare costs.
Learn from experts including: 
  • Philippe Barillon, Global Head Insights & Analytics - Cardio-Renal-Metabolic Franchise, Novartis
  • Mike Devoy, CMO, Executive VP, Medical Affairs & Pharmacovigilance, Bayer
  • Dr Oleksandr Gorbenko, Global Patient Affairs Director, Neurosciences, Ipsen
  • Jeanne Kehren, SVP Digital & Commercial Innovation & CIO, Bayer
  • Connie Montgomery, Patient advocate
  • Lilly Stairs, Founder & Principal, Patient Authentic
  • Julia Walsh, CEO, Brand Medicine International
  • Charlotta Norgaard, CEO and Co-Founder, Patient in Focus
  • Benoit Brouard, CEO and Co-founder, Wefight
  • Rafael Ayoub, Medical Advisor,, Wefight
Don’t hesitate to get in touch with any feedback.

Kind regards,
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.

Address therapeutic inertia to mitigate poor patient outcomes – download your whitepaper now 

Fill in your details below to learn from patient advocates and leaders from Bayer, Ipsen, Novartis and more!
Reuters Events will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy: